<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897142</url>
  </required_header>
  <id_info>
    <org_study_id>B2341001</org_study_id>
    <secondary_id>2013-001387-36</secondary_id>
    <nct_id>NCT01897142</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what the study drug does to the body, what the body
      does to the study drug, and if the study drug is safe and well tolerated when given to adult
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting treatment related adverse events</measure>
    <time_frame>Through Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, severity and causal relationship of treatment emergent adverse events, treatment emergent serious adverse events, and withdrawals due to treatment emergent adverse events</measure>
    <time_frame>Through Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and magnitude of treatment emergent abnormal laboratory findings</measure>
    <time_frame>Through Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital sign measurements, ECG parameters, and physical examinations</measure>
    <time_frame>Through Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by prothrombin time/internationalize normalized ration (PT/INR)</measure>
    <time_frame>Through post dose Day3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT)</measure>
    <time_frame>Through post dose Day3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by thrombin-antithrombin (TAT) complexes</measure>
    <time_frame>Through post dose Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by prothrombin fragments 1+2 (PF1+2)</measure>
    <time_frame>Through post dose Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by D-dimer</measure>
    <time_frame>Through post dose Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by protein C activity</measure>
    <time_frame>Through post dose Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by Factor V activity</measure>
    <time_frame>Through post dose Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibody immune response</measure>
    <time_frame>Through post dose Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor X activity</measure>
    <time_frame>Through post dose Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>1 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>2 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>3 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>5 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects.

          -  Healthy non-child bearing female subjects.

          -  18 to 35 years of age.

        Exclusion Criteria:

          -  Heart disease.

          -  Clotting disorders.

          -  Use of nicotine products.

          -  Diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2341001&amp;StudyName=A%20Phase%201%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Pf-05230907%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

